title: ÐÑÐµÐ½ÐºÐ° ÑÑÑÐµÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ Ð¿ÐµÐ¿ÑÐ¸Ð´Ð° ÐÐ1 Ð¸ ÐºÐ°ÑÐ¸Ð¾Ð½Ð½ÑÑ Ð»Ð¸Ð¿Ð¾ÑÐ¾Ð¼ Ð² ÐºÐ°ÑÐµÑÑÐ²Ðµ ÑÑÐµÐ´ÑÑÐ² Ð´Ð¾ÑÑÐ°Ð²ÐºÐ¸ Ð¼Ð¸Ð ÐÐ Ð½Ð° Ð¼Ð¾Ð´ÐµÐ»Ð¸ Ñ ÑÐ¾Ð½Ð¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð¼Ð¸ÐµÐ»Ð¾Ð»ÐµÐ¹ÐºÐ¾Ð·Ð° in vitro
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: Efficiency evaluation of EB1 peptide and cationic liposomes as siRNA delivery system in chronic myeloid leukemia model in vitro
Creators: name: ÐÐ¾Ð²Ð±ÑÑ, ÐÐ»ÐµÑÑ
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2023
Subjects: Ð³ÐµÐ½Ð½Ð°Ñ ÑÐµÑÐ°Ð¿Ð¸Ñ
Ð¿ÑÐ¾Ð½Ð¸ÐºÐ°ÑÑÐ¸Ðµ Ð² ÐºÐ»ÐµÑÐºÑ Ð¿ÐµÐ¿ÑÐ¸Ð´Ñ
ÐºÐ°ÑÐ¸Ð¾Ð½Ð½ÑÐµ Ð»Ð¸Ð¿Ð¾ÑÐ¾Ð¼Ñ
Ð¼Ð°Ð»ÑÐµ Ð¸Ð½ÑÐµÑÑÐµÑÐ¸ÑÑÑÑÐ¸Ðµ Ð ÐÐ
Ñ ÑÐ¾Ð½Ð¸ÑÐµÑÐºÐ¸Ð¹ Ð¼Ð¸ÐµÐ»Ð¾Ð»ÐµÐ¹ÐºÐ¾Ð·
gene therapy
cell-penetrating peptides
cationic liposomes
small interfering RNA
chtonic myeloid leukemia

description: Ð¡ Ð¼Ð¾Ð¼ÐµÐ½ÑÐ° ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ¸ ÐºÐ¾Ð½ÑÐµÐ¿ÑÐ¸Ð¸ Ð³ÐµÐ½Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð¿ÑÐ¾ÑÐ»Ð¾ ÑÐ¶Ðµ Ð±Ð¾Ð»ÐµÐµ 50 Ð»ÐµÑ, Ð¾Ð´Ð½Ð°ÐºÐ¾ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ Ð¿Ð¾ Ð¿Ð¾Ð¸ÑÐºÑ ÑÑÑÐµÐºÑÐ¸Ð²Ð½ÑÑ Ð¸ Ð±ÐµÐ·Ð¾Ð¿Ð°ÑÐ½ÑÑ ÑÑÐµÐ´ÑÑÐ² Ð´Ð¾ÑÑÐ°Ð²ÐºÐ¸ ÑÐµÑÐ°Ð¿ÐµÐ²ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð½ÑÐºÐ»ÐµÐ¸Ð½Ð¾Ð²ÑÑ ÐºÐ¸ÑÐ»Ð¾Ñ Ð¾ÑÑÐ°ÑÑÑÑ Ð°ÐºÑÑÐ°Ð»ÑÐ½ÑÐ¼Ð¸ Ð¸Ð·-Ð·Ð° Ð½Ð¸Ð·ÐºÐ¾Ð³Ð¾ ÐºÐ¾Ð»Ð¸ÑÐµÑÑÐ²Ð° Ð¾Ð´Ð¾Ð±ÑÐµÐ½Ð½ÑÑ Ð³ÐµÐ½Ð¾ÑÐµÑÐ°Ð¿ÐµÐ²ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð¿ÑÐµÐ¿Ð°ÑÐ°ÑÐ¾Ð². ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð¾ÑÐµÐ½ÐºÐµ ÑÑÑÐµÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ Ð¿ÑÐ¾Ð½Ð¸ÐºÐ°ÑÑÐµÐ³Ð¾ Ð² ÐºÐ»ÐµÑÐºÑ Ð¿ÐµÐ¿ÑÐ¸Ð´Ð° EB1 Ð¸ ÐºÐ°ÑÐ¸Ð¾Ð½Ð½ÑÑ Ð»Ð¸Ð¿Ð¾ÑÐ¾Ð¼ 2Ð¥3-DOPE+DSPE-PEG2000 (0.62%) Ð² ÐºÐ°ÑÐµÑÑÐ²Ðµ ÑÑÐµÐ´ÑÑÐ² Ð´Ð¾ÑÑÐ°Ð²ÐºÐ¸ Ð¼Ð°Ð»ÑÑ Ð¸Ð½ÑÐµÑÑÐµÑÐ¸ÑÑÑÑÐ¸Ñ Ð ÐÐ (Ð¼Ð¸Ð ÐÐ). Ð£Ð´Ð¾Ð±Ð½Ð¾Ð¹ Ð¼Ð¾Ð´ÐµÐ»ÑÑ Ð´Ð»Ñ ÑÑÐ¾Ð³Ð¾ ÑÐ²Ð»ÑÐµÑÑÑ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ðµ ÑÑÐ¾Ð½Ð¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð¼Ð¸ÐµÐ»Ð¾Ð»ÐµÐ¹ÐºÐ¾Ð·Ð°, ÑÐ°Ð·Ð²Ð¸Ð²Ð°ÑÑÐµÐµÑÑ Ð² ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð²Ð¾Ð·Ð½Ð¸ÐºÐ½Ð¾Ð²ÐµÐ½Ð¸Ñ Ð¾Ð´Ð½Ð¾Ð¹ ÑÑÐ¾Ð¼Ð¾ÑÐ¾Ð¼Ð½Ð¾Ð¹ Ð¼ÑÑÐ°ÑÐ¸Ð¸, Ð¿ÑÐ¸Ð²Ð¾Ð´ÑÑÐµÐ¹ Ðº Ð¾Ð±ÑÐ°Ð·Ð¾Ð²Ð°Ð½Ð¸Ñ Ð¾Ð½ÐºÐ¾Ð³ÐµÐ½Ð° BCR-ABL, Ð±ÐµÐ»ÐºÐ¾Ð²ÑÐ¹ Ð¿ÑÐ¾Ð´ÑÐºÑ ÐºÐ¾ÑÐ¾ÑÐ¾Ð³Ð¾ ÑÑÐ¸Ð¼ÑÐ»Ð¸ÑÑÐµÑ Ð°Ð½Ð¾Ð¼Ð°Ð»ÑÐ½ÑÑ Ð¿ÑÐ¾Ð»Ð¸ÑÐµÑÐ°ÑÐ¸Ñ ÐºÐ»ÐµÑÐ¾Ðº. ÐÐ° Ð¿ÐµÑÐ²Ð¾Ð¼ ÑÑÐ°Ð¿Ðµ ÐºÐ¾Ð¼Ð¿Ð»ÐµÐºÑÑ Ð¼Ð¸Ð ÐÐ Ñ Ð¿ÐµÐ¿ÑÐ¸Ð´Ð¾Ð¼ EB1, Ð° ÑÐ°ÐºÐ¶Ðµ Ñ ÐºÐ°ÑÐ¸Ð¾Ð½Ð½ÑÐ¼Ð¸ Ð»Ð¸Ð¿Ð¾ÑÐ¾Ð¼Ð°Ð¼Ð¸ Ð±ÑÐ»Ð¸ Ð¿Ð¾Ð»ÑÑÐµÐ½Ñ Ð¸ Ð¾ÑÐ°ÑÐ°ÐºÑÐµÑÐ¸Ð·Ð¾Ð²Ð°Ð½Ñ. ÐÐ° ÑÐ»ÐµÐ´ÑÑÑÐµÐ¼ ÑÑÐ°Ð¿Ðµ Ð±ÑÐ»Ð° Ð¾ÑÐµÐ½ÐµÐ½Ð° ÑÑÑÐµÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑ ÑÑÐ°Ð½ÑÑÐµÐºÑÐ¸Ð¸ ÐºÐ»ÐµÑÐ¾Ðº Ð-562 ÐºÐ¾Ð¼Ð¿Ð»ÐµÐºÑÐ°Ð¼Ð¸ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ Ð¿ÑÐ¾ÑÐ¾ÑÐ½Ð¾Ð¹ ÑÐ¸ÑÐ¾ÑÐ»ÑÐ¾ÑÐ¸Ð¼ÐµÑÑÐ¸Ð¸ Ð¸ ÐºÐ¾Ð½ÑÐ¾ÐºÐ°Ð»ÑÐ½Ð¾Ð¹ Ð¼Ð¸ÐºÑÐ¾ÑÐºÐ¾Ð¿Ð¸Ð¸. Ð­ÑÑÐµÐºÑ Ð¼Ð¸Ð ÐÐ Ð¿ÑÐ¸ Ð´Ð¾ÑÑÐ°Ð²ÐºÐµ Ð¸ÑÑÐ»ÐµÐ´ÑÐµÐ¼ÑÐ¼Ð¸ ÐºÐ¾Ð¼Ð¿Ð»ÐµÐºÑÐ°Ð¼Ð¸ Ð¾ÑÐµÐ½Ð¸Ð²Ð°Ð»Ð¸ Ð¿Ð¾ ÑÐ½Ð¸Ð¶ÐµÐ½Ð¸Ñ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð° BCR-ABL, Ð° ÑÐ°ÐºÐ¶Ðµ Ð¿Ð¾ ÑÐ¼ÐµÐ½ÑÑÐµÐ½Ð¸Ñ ÑÑÐ¾Ð²Ð½Ñ Ð°Ð½Ð¾Ð¼Ð°Ð»ÑÐ½Ð¾Ð¹ Ð¿ÑÐ¾Ð»Ð¸ÑÐµÑÐ°ÑÐ¸Ð¸ ÐºÐ»ÐµÑÐ¾Ðº Ð-562. ÐÑÐ»Ð¾ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð¾, ÑÑÐ¾ ÐºÐ°ÑÐ¸Ð¾Ð½Ð½ÑÐµ Ð»Ð¸Ð¿Ð¾ÑÐ¾Ð¼Ñ 2Ð¥3-DOPE+DSPE-PEG2000 (0.62%) Ð±Ð¾Ð»ÐµÐµ ÑÑÑÐµÐºÑÐ¸Ð²Ð½Ð¾ Ð´Ð¾ÑÑÐ°Ð²Ð»ÑÑÑ Ð¼Ð¸Ð ÐÐ Ð² ÐºÐ»ÐµÑÐºÐ¸ Ð½Ð° Ð¼Ð¾Ð´ÐµÐ»Ð¸ ÑÑÐ¾Ð½Ð¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð¼Ð¸ÐµÐ»Ð¾Ð»ÐµÐ¹ÐºÐ¾Ð·Ð° in vitro.
description: More than 50 years have passed since the concept of gene therapy was developed. However, research to find effective and safe delivery vectors of therapeutic nucleic acids remains relevant due to the low number of approved gene therapy drugs. The given work is devoted to efficiency evaluation of cell-penetrating peptide (CPP) EB1 and 2Ð¥3-DOPE+DSPE-PEG2000 (0.62%) cationic liposomes as small interfering RNA (siRNA) delivery system. Chronic myelogenous leukemia is a convenient model for this because this disease develops as a result of a single chromosomal mutation leading to the formation of oncogene BCR-ABL. The protein product of this gene stimulates abnormal cell proliferation. In the first step, siRNA complexes with EB1 peptide and with cationic liposomes were obtained and characterized. At the next stage, the efficiency of transfection of K-562 cells by the studied complexes was evaluated using flow cytofluorimetry and confocal microscopy. The effect of siRNA which was delivered by the studied complexes was analyzed by reducing of BCR-ABL gene expression and by a decrease of K-562 cell abnormal proliferation. The study showed that the use of 2Ð¥3-DOPE+DSPE-PEG2000 (0.62%) cationic liposomes for siRNA delivery into cells was more effective in chronic myeloid leukemia model in vitro.